Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locallyadvanced hypopharynx and base of tongue cancer
- Author:
Sung Hee LIM
1
;
Jong-Mu SUN
;
Joohyun HONG
;
Dongryul OH
;
Yong Chan AHN
;
Man Ki CHUNG
;
Han-Sin JEONG
;
Young-Ik SON
;
Myung-Ju AHN
;
Chung-Hwan BAEK
;
Keunchil PARK
Author Information
- Publication Type:2
- From:The Korean Journal of Internal Medicine 2021;36(Suppl 1):S217-S224
- CountryRepublic of Korea
- Language:English
- Abstract: Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investigated the role of IC in improving outcome over current chemoradiotherapy (CRT) in patients with hypopharynx and BOT cancer. Methods: Treatment-naïve patients with stage III/IV (M0) hypopharynx or BOT cancer were randomly assigned to receive CRT alone (CRT arm: cisplatin 100 mg/m2 on D1 3-weekly, two times plus radiotherapy 68.4 Gy/30 fractions on weekdays) versus two 21-day cycles of IC with TPF (docetaxel & cisplatin 75 mg/m2 on D1, and fluorouracil 75 mg/m2 on D1-4) followed by the same CRT regimen (IC arm). The primary endpoint was progression-free survival (PFS). Results: This study closed early after enrollment of 36 patients (19 in the CRT arm, 17 in the IC arm). After a median follow-up of 47.2 months, there was no significant difference in PFS: the median PFS was 26.8 months for the CRT arm and was not reached for the IC arm (p = 0.13). However, the survival curves were widely separated with a plateau after 3 years, suggesting a potential survival benefit from IC: 3-year PFS rates were 45% and 68%, and 3-year overall survival rates were 56% and 86%, in the CRT and IC arms, respectively. Conclusions: This study failed to demonstrate that induction TPF chemotherapy improves survival in patients with BOT and hypopharynx cancer. However, it suggested a favorable outcome with IC to this population.
